As the studies performed so far suggest a critical involvement of caspases and the apoptotic regulator Bcl-2 in the etiology associated with AD it has been thought that the development of caspase inhibitors or compounds that increase expression of Bcl-2 in the brain can be looked as effective therapeutic targets. Although Bcl-2 agonists are innovative antiapoptotic approaches no selective agonist has yet been reported (Rohn and Head, 2009).